Truvestments Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Truvestments Capital’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12K	Hold	138	–	–	﹤0.01%	728
2025 Q4	$14.8K	Hold	138	–	–	﹤0.01%	636
2025 Q3	$13.9K	Hold	138	–	–	﹤0.01%	657
2025 Q2	$8.72K	Hold	138	–	–	﹤0.01%	660
2025 Q1	$7.31K	Hold	138	–	–	﹤0.01%	701
2024 Q4	$7.72K	Hold	138	–	–	﹤0.01%	645
2024 Q3	$7.23K	Buy	+138	New	+$6.61K	﹤0.01%	627
2024 Q2	–	Sell	-216	Closed	-$9.36K	–	593
2024 Q1	$9.36K	Hold	216	–	–	﹤0.01%	503
2023 Q4	$9.93K	Hold	216	–	–	﹤0.01%	519
2023 Q3	$4.95K	Hold	216	–	–	﹤0.01%	514
2023 Q2	$3.56K	Hold	216	–	–	﹤0.01%	561
2023 Q1	$3.85K	Buy	+216	New	+$5.42K	﹤0.01%	533

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Truvestments Capital's RYTM Position: Q1 2026 in Review

Truvestments Capital held its Rhythm Pharmaceuticals (RYTM) position steady in Q1 2026 at 138 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #728.

Truvestments Capital first reported a position in RYTM in Q1 2023 and has held it in 12 quarters since. The position peaked at $14.8K in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

Truvestments Capital held 138 shares of Rhythm Pharmaceuticals worth $12K as of Q1 2026.
Truvestments Capital left its Rhythm Pharmaceuticals share count unchanged in Q1 2026.
Rhythm Pharmaceuticals made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #728 holding.
Truvestments Capital first reported a position in Rhythm Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
Truvestments Capital's Rhythm Pharmaceuticals position peaked at $14.8K in Q4 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.